Guardant360 TissueNext™
Home » Guardant360 TissueNext™

guardant_360_TissueNext_logo

Results from a tissue biopsy available when needed

Our Guardant360 TissueNext™ tissue biopsy test offers comprehensive genomic profiling to find actionable information when tissue testing is appropriate.

The latest addition to our portfolio of tests, the Guardant360 TissueNext™ test, can help improve the management of patients with advanced stage cancers.

Guardant360 TissueNext™ is an analytically validated comprehensive next-generation sequencing panel that includes clinically actionable biomarkers to enable informed treatment decisions for patients with advanced solid tumors.

The Guardant360 TissueNext™ test, the company’s first tissue-based test can help oncologists identify patients with advanced cancer who may benefit from biomarker-informed treatment.

The Guardant360 TissueNext™ test report will include Tumor Mutational Burden (TMB), Microsatellite Instability (MSI) status, Homologous Recombination Repair (HRR) genes and selected fusions.

Easy to interpret report using an analytically validated panel that includes clinically relevant biomarkers, TMB, MSI status, and selected fusion genes. 

Delivering fast, reliable test results

Guardant360 TissueNext™ delivers results in two weeks. Guardant360 TissueNext can help improve the management of patients with advanced stage cancers.

Message us